NXP800
规格
| Cas Number | 1693734-80-3 |
| 规格或纯度 | ≥99% |
| 纯度 | ≥99% |
| 包装 | 50mg 或 10mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | DMSO : 100 mg/mL (175.55 mM; Need ultrasonic) |
| 过滤标签 | HSP,Cell Cycle/DNA Damage,Metabolic Enzyme/Protease |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | NXP800 (CCT361814) 是一种强效的口服活性热休克因子 1 (HSF1) 通路抑制剂。NXP800 具有癌症研究的潜力。 |
| 英文描述 |
NXP800 (CCT361814) is a potent and orally active heat shock factor 1 (HSF1) pathway inhibitor. NXP800 has the potential for cancer research In Vitro NXP800 (example 169) inhibits U20S cells viability (IC 50 =0.056 μM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo NXP800 (35 mg/kg; po; once daily for 20 days) inhibits the established SK-OV-3 human ovarian cancer solid tumor xenografts grown subcutaneously, with tumor growth inhibition (TGI) of 120% relative to control. Pharmacokinetic AnalysisSpecies Route Dose (mg/kg) T max (h) AUC last (ng·h/mL) Cl tb (mL/min/kg) t 1/2 (h) F (%) AUC u 0-t (h·nM) Free C av 0-24h (nM) Cl u (mL/min/kg) mouse po/iv 5/5 2.0 6000 (7800-4600) (po) 10 (10-9.7) (iv) 4.0 42 (po) 72 3.3 830 (iv) rat po/iv 5/1 6.0 2600 (po) 24 (iv) 3.1 45 (po) 86 3.7 730 (iv) dog po/iv 2.5/0.5 2.0 250 (po) 21 (iv) 1.4 9.1 (po) 35 1.9 150 (iv) MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:HSF1 |